Prevalence and factors associated with self-medication for COVID-19 prevention using disproven drugs in Peru: a cross-sectional nationwide study

A. Hernández-Vásquez, Fabriccio J Visconti-Lopez, Dustin M Solorzano-Salazar, Antonio Barrenechea-Pulache
{"title":"Prevalence and factors associated with self-medication for COVID-19 prevention using disproven drugs in Peru: a cross-sectional nationwide study","authors":"A. Hernández-Vásquez, Fabriccio J Visconti-Lopez, Dustin M Solorzano-Salazar, Antonio Barrenechea-Pulache","doi":"10.18549/pharmpract.2023.4.2877","DOIUrl":null,"url":null,"abstract":"Objective: The objective of this study was to identify the prevalence and factors associated with the use of drugs without evidence for the prevention of COVID-19 in Peruvians without symptoms or diagnosis, using the National Household Survey (ENAHO) 2021. Methods: A secondary analysis was made of the ENAHO 2021. We evaluated participants older than 18 years who did not undergo any test to diagnose COVID-19 and used any drug to prevent COVID-19. Adjusted prevalence ratios (aPRs) were estimated to determine the associated factors. Results: Among the 69,815 participants analyzed, the prevalence of taking a drug 4 weeks prior to the survey was 5.64%. Factors associated with drug consumption were: age 30-59 years (aPR 1.47; 95% confidence interval [CI]: 1.32-1.65); having a higher education (aPR 1.73; 95% CI:1.28-2.33); having a chronic disease (aPR 1.40; 95% CI: 1.26-1.56); not having poverty status (aPR 1.40; 95% CI: 1.26-1.56); living in an urban area (aPR 1.61; 95% CI: 1.31-1.99). Meanwhile, living in the highlands (aPR 0.77; 95% CI: 0.60-0.97) and not having a landline, cell phone, television or internet at home (aPR 0.65; 95% CI: 0.43-0.98) were protective factors from unnecessary drug consumption. Conclusion: It is concerning that even after one year of living with the pandemic and having refuted the utility of medications such as ivermectin and azithromycin, these drugs are still widely consumed by a sector of the population without symptoms or a diagnosis of COVID-19. Therefore, it is necessary to formulate and implement public health measures that address this problem, considering the associated factors to reduce this consumption.","PeriodicalId":516653,"journal":{"name":"Pharmacy Practice","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18549/pharmpract.2023.4.2877","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The objective of this study was to identify the prevalence and factors associated with the use of drugs without evidence for the prevention of COVID-19 in Peruvians without symptoms or diagnosis, using the National Household Survey (ENAHO) 2021. Methods: A secondary analysis was made of the ENAHO 2021. We evaluated participants older than 18 years who did not undergo any test to diagnose COVID-19 and used any drug to prevent COVID-19. Adjusted prevalence ratios (aPRs) were estimated to determine the associated factors. Results: Among the 69,815 participants analyzed, the prevalence of taking a drug 4 weeks prior to the survey was 5.64%. Factors associated with drug consumption were: age 30-59 years (aPR 1.47; 95% confidence interval [CI]: 1.32-1.65); having a higher education (aPR 1.73; 95% CI:1.28-2.33); having a chronic disease (aPR 1.40; 95% CI: 1.26-1.56); not having poverty status (aPR 1.40; 95% CI: 1.26-1.56); living in an urban area (aPR 1.61; 95% CI: 1.31-1.99). Meanwhile, living in the highlands (aPR 0.77; 95% CI: 0.60-0.97) and not having a landline, cell phone, television or internet at home (aPR 0.65; 95% CI: 0.43-0.98) were protective factors from unnecessary drug consumption. Conclusion: It is concerning that even after one year of living with the pandemic and having refuted the utility of medications such as ivermectin and azithromycin, these drugs are still widely consumed by a sector of the population without symptoms or a diagnosis of COVID-19. Therefore, it is necessary to formulate and implement public health measures that address this problem, considering the associated factors to reduce this consumption.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
秘鲁使用假药自我治疗以预防 COVID-19 的流行率和相关因素:一项全国性横断面研究
研究目的本研究的目的是利用 2021 年全国住户调查(ENAHO),确定无症状或无诊断的秘鲁人使用无证据预防 COVID-19 药物的流行率和相关因素。调查方法对ENAHO 2021进行了二次分析。我们对 18 岁以上未接受任何 COVID-19 诊断检查、未使用任何药物预防 COVID-19 的参与者进行了评估。我们估算了调整流行率 (aPR),以确定相关因素。结果:在分析的 69,815 名参与者中,调查前 4 周服用药物的流行率为 5.64%。与吸毒相关的因素有:年龄 30-59 岁(aPR 1.47;95% 置信区间[CI]:1.32-1.65);受过高等教育(aPR 1.73;95% 置信区间:1.28-2.33);患有慢性疾病(aPR 1.40;95% 置信区间:1.26-1.56);无贫困状况(aPR 1.40;95% 置信区间:1.26-1.56);居住在城市地区(aPR 1.61;95% 置信区间:1.31-1.99)。同时,居住在高原地区(aPR 0.77;95% CI:0.60-0.97)和家中没有固定电话、手机、电视或互联网(aPR 0.65;95% CI:0.43-0.98)是避免不必要药物消费的保护因素。结论令人担忧的是,即使在与大流行病共存一年并驳斥了伊维菌素和阿奇霉素等药物的效用之后,仍有一部分无症状或未确诊为 COVID-19 的人群在广泛使用这些药物。因此,有必要制定和实施公共卫生措施来解决这一问题,同时考虑到减少这种消费的相关因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Perception and Knowledge of Students of Medical Colleges towards Dietary Supplements Use for Prevention andTreatment of COVID-19 A review of the career choices of Sefako Makgatho Health Sciences University pharmacy graduates from 2015 to 2019 – A pilot study Impact of magnesium infusion rate on serum magnesium level after magnesium replacement in hospitalized surgical patients with hypomagnesemia: A 11-year retrospective cohort study Integration of Clinical Pharmacy Services in Primary Healthcare in the United Arab Emirates: Indicators and Impacts Predictors of adherence to diabetes medications: multicentre study from the Eastern Province, Saudi Arabia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1